Related Experiment Video
Updated: May 27, 2025
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
The impact of SGLT-2 Inhibitors on the Risk of Atrial Fibrillation in Heart Failure
Insights
Sodium-glucose cotransporter-2 inhibitors (SGLT2i) significantly reduce the risk of new-onset atrial fibrillation (AF) in patients hospitalized for heart failure (HF). This therapy also delays the onset of AF in this vulnerable population.
Area of Science:
- Cardiology
- Pharmacology
- Internal Medicine
Background:
- Heart failure (HF) and atrial fibrillation (AF) are comorbid conditions, with each potentially worsening the other.
- Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have demonstrated efficacy in managing HF, but their impact on AF development in HF patients remains unclear.
Purpose of the Study:
- To investigate the association between SGLT2 inhibitor therapy and the incidence of new-onset AF in patients hospitalized with heart failure.
Main Methods:
- A retrospective analysis of patients hospitalized with a primary HF diagnosis and no prior AF history over a three-year period.
- The primary endpoint was the occurrence of new-onset AF within 12 months post-hospitalization.
- Hazard ratios and Kaplan-Meier survival analyses were used to assess the effect of SGLT2i on AF development.
Main Results:
- SGLT2i use was linked to a significantly lower risk of developing AF (HR 0.69, p=0.002) across all HF ejection fraction subtypes.
- Kaplan-Meier analysis showed reduced AF-free survival in patients not on SGLT2i therapy across various subgroups (diabetes, hypertension, CAD, age, BMI).
- SGLT2i use was associated with a lower incidence (12.1% vs 19.5%) and delayed onset (339 vs 317 days) of AF compared to non-users.
Conclusions:
- SGLT2 inhibitor therapy is associated with a significantly reduced risk of developing new-onset atrial fibrillation in patients following hospitalization for heart failure.
Background:
Heart failure (HF) and atrial fibrillation (AF) are closely linked, each exacerbating the other. While sodium-glucose cotransporter-2 inhibitors (SGLT2i) are known to provide substantial benefits in HF management, their effect on AF incidence in this population is not well-defined.
Objective:
This study aims to assess the effect of SGLT2i therapy on the development of new-onset AF in patients with HF.
Methods:
This retrospective analysis included all patients hospitalized with a primary diagnosis of HF and no prior diagnosis of AF over a 3-year period. The primary outcome was the occurrence of new-onset AF within 12 months following HF hospitalization.
Results:
Of 3,953 patients 720 (18.2%) developed AF within one year. SGLT2i use was associated with significantly lower risk of AF ( HR 0.69, 95% CI:0.55-0.87; p=0.002 ) across all HF types-reduced, mid-range, and preserved ejection fraction. Kaplan-Meier survival analysis revealed significantly reduced AF-free survival in patients not on SGLT2i therapy, compared to patients on SGLT2i therapy, across subgroups categorized by diabetes, hypertension, coronary artery disease, age ≥65 years, and BMI ≥30Kg/m 2 (p <0.05 for all). Among those who developed AF, SGLT2i use had significantly lower incidence of AF during follow-up as compared to when not used (12.1% vs. 19.5%, p<0.001). SGLT2 use also delayed onset of AF compared to those not treated with an SGLT2i (339 ± 80 days vs. 317 ± 106 days; p<0.001 ).
Conclusions:
The use of SGLT2i therapy is associated with a significantly lower risk of the developing AF following hospitalization for HF.
Related Concept Videos
01:23Dipeptidyl Peptidase 4 Inhibitors
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are...
01:26Heart Failure Drugs: Inotropic Agents
01:17Oral Hypoglycemic Agents: Sulfonylureas